Results 71 to 80 of about 2,272 (175)

Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022

Microbiology Spectrum
Eravacycline is a synthetic fluorocycline approved by the U.S. Food and Drug Administration in 2018. This study aimed to describe clinical and microbiological outcomes in addition to associated adverse effects of eravacycline used in U.S. hospitals. Real-
Ashlan J. Kunz Coyne, Sara Alosaimy, Kristen Lucas, Abdalhamid M. Lagnf, Taylor Morrisette, Kyle C. Molina, Alaina DeKerlegand, Melanie Rae Schrack, S. Lena Kang-Birken, Athena L.V. Hobbs, Jazmin Agee, Nicholson B. Perkins, Mark Biagi, Michael Pierce, James Truong, Justin Andrade, Jeannette Bouchard, Tristan Gore, Madeline A. King, Benjamin M. Pullinger, Kimberly C. Claeys, Shelbye Herbin, Reese Cosimi, Serina Tart, Michael P. Veve, Bruce M. Jones, Leonor M. Rojas, Amy K. Feehan, Marco R. Scipione, Jing J. Zhao, Paige Witucki, Michael J. Rybak   +31 more
doaj   +1 more source

A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline

Infectious Diseases and Therapy, 2020
Background Eravacycline is a novel fluorocycline approved for treatment of intraabdominal infections, with a broad spectrum of activity against a range of pathogens including multidrug-resistant species, including ESBL- or KPC-producing isolates.
Nicholas Van Hise, Russell M. Petrak, Nathan C. Skorodin, Robert M. Fliegelman, Michael Anderson, Vishal Didwania, Alice Han, Kairav Shah, Vishnu Chundi, David Hines, Ingrid Roig, Apoorv Kalra   +11 more
doaj   +1 more source

Innovative Wirkstoffe aus der antibakteriellen Forschung im Kampf gegen mikrobielle Resistenzen

Angewandte Chemie, Volume 137, Issue 10, March 3, 2025.
Dieser Artikel gewährt einen Überblick über in den letzten drei Jahrzehnten untersuchte antibakteriellen Wirkstoffe. Aspekte der Herkunft, der zellulären Targetstrukturen, des antibakteriellen Wirkspektrums und dem Nachweis der Wirksamkeit in Tierstudien werden zusammen mit aktuellen Entwicklungen beleuchtet.
Roderich D. Süssmuth, Marcel Kulike‐Koczula, Peng Gao, Simone Kosol   +3 more
wiley   +1 more source

Eravacycline (TP-434) Is Efficacious in Animal Models of Infection [PDF]

Antimicrobial Agents and Chemotherapy, 2015
ABSTRACT Eravacycline is a novel broad-spectrum fluorocycline antibiotic being developed for a wide range of serious infections. Eravacycline was efficacious in mouse septicemia models, demonstrating 50% protective dose (PD 50 ) values of ≤1 mg/kg of body weight once a day (q.d.) against ...
Trudy H, Grossman, Timothy M, Murphy, Andrew M, Slee, Denene, Lofland, Joyce A, Sutcliffe   +4 more
openaire   +2 more sources

Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research

Angewandte Chemie International Edition, Volume 64, Issue 10, March 3, 2025.
This article provides an overview over antibacterial drugs investigated in the past three decades. Aspects of the compound's origins, their cellular targets, the antibacterial spectrum and proof‐of‐concept in animal studies are covered and current trends are highlighted.
Roderich D. Süssmuth, Marcel Kulike‐Koczula, Peng Gao, Simone Kosol   +3 more
wiley   +1 more source

Switching Residues: Eine Plattform zur Synthese von Fidaxomicin Antibiotika

Angewandte Chemie, Volume 137, Issue 7, February 10, 2025.
Residue Switching: Das Einführen zusätzlicher Substituenten in Naturstoffe erhöht ihr Molekulargewicht und oft auch ihre Lipophilie. Wir haben ein Pd‐katalysiertes Protokoll entwickelt, um das komplexe Rhamnosid‐Aren‐Fragment des Antibiotikums Fidaxomicin in einem Schritt vom ungeschützten Naturstoff direkt durch einfache Amine zu ersetzen.
Erik Jung, Tizian Griesser, Jordan Costafrolaz, Ondine Duverger, Yves Mattenberger, Silvia Dittmann, Andrea Dorst, Alexander Major, David Dailler, Daniel Schäfle, Susanne Sievers, Konstantin Brodolin, Patrick H. Viollier, Peter Sander, Karl Gademann   +14 more
wiley   +1 more source

Switching Residues: A Platform for the Synthesis of Fidaxomicin Antibiotics

Angewandte Chemie International Edition, Volume 64, Issue 7, February 10, 2025.
Switching residues: Adding new substituents to natural products increases their molecular weight and often their lipophilicity. We developed a Pd‐catalysed protocol to directly replace the rhamnoside‐arene fragment of the antibiotic fidaxomicin with simple amines in 1 step from the unprotected natural product.
Erik Jung, Tizian Griesser, Jordan Costafrolaz, Ondine Duverger, Yves Mattenberger, Silvia Dittmann, Andrea Dorst, Alexander Major, David Dailler, Daniel Schäfle, Susanne Sievers, Konstantin Brodolin, Patrick H. Viollier, Peter Sander, Karl Gademann   +14 more
wiley   +1 more source

Unusual Presentation of Mycobacterium abscessus Thigh Mass: A Case Report

Case Reports in Infectious Diseases, Volume 2025, Issue 1, 2025.
Mycobacterium abscessus is a rapidly growing non‐tuberculous Mycobacterium (NTM) primarily associated with pulmonary infections, particularly in individuals with underlying lung conditions. While soft tissue infections are less common, their incidence has been increasing.
Ryan J. Blake, Grant R. McChesney, H. James Williams, Steven M. Holland, Allison M. Lastinger, Piyush Baindara   +5 more
wiley   +1 more source

Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae

, 2019
This study investigated the characteristics and mechanisms of eravacycline resistance and heteroresistance in clinical Klebsiella pneumoniae isolates. A total of 393 clinical K.
Jin-xin Zheng (4876861), Zhong Chen (32985), Di Qu (66686), Zhi-wei Lin (1892365), Wei-hong Lin (6535811), Xiang Sun (553464), Zhi-jian Yu (4876864), Guo-bin Qi (6535814), Qi-wen Deng (4876867), Yang Wu (66682)   +9 more
core   +1 more source

Carbapenem‐Resistant Klebsiella pneumoniae Isolated From a Patient in a Midwestern U.S. Hospital With a History of Indian Travel: Therapeutic Strategies and Clinical Outcomes

Case Reports in Infectious Diseases, Volume 2025, Issue 1, 2025.
Carbapenemases have had increasing prevalence within the United States and worldwide. Here, we present a case of carbapenem‐resistant Klebsiella pneumoniae (CRKP) which is unique due to the rarity of multiple mechanisms of resistance within the Klebsiella pneumoniae harboring New Delhi metallo‐β‐lactamases (NDM), oxacillinase‐48 (OXA‐48)‐like, and ...
Christopher Phan, Kristen Tsai, Christian M. Gill, Robin Chamberland, Christian Hendrix, Rong Hou, Dawei Cui   +6 more
wiley   +1 more source